Hand eczema is often a chronic, multifactorial disease. It is usually related to occupational or routine household activities. It is mainly affecting the palms but can affect other parts of the hand, too. The main symptoms are dry, itchy skin that is red or darker than the surrounding skin. Other symptoms include cracking, soreness, and bleeding. In some cases, blisters may develop. The skin is generally dry, scaly, and thickened, and the fingers can become swollen when the eczema is flaring. If the eczema is severe over a long time, the hands can become very painful, making it difficult to carry out day-to-day tasks such as doing up buttons, holding a pen, or using a computer. The skin forms part of the immune system and helps to protect against infection. It not only provides a physical barrier, but the layers of skin contain specialized cells that destroy invading foreign proteins such as bacteria and viruses. In people with eczema, the immune system overreacts in the skin, making it inflamed and itchy.
Occupational factors play a role, and certain professionals with frequent hand washing or exposure to harsh substances face a higher risk. Adapting work practices, using protective gloves, and maintaining good hand hygiene are essential preventive measures. It is important to avoid any known irritants or allergens as it is to apply emollients and other treatments as necessary. Emollients are medical moisturizers that come in different formulations. There are lotions, creams, gels, ointments, and a spray. They are available on prescription from a GP and to buy over-the-counter in pharmacies. Several companies work on their medicines to provide patients with an accurate product.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/chronic-hand-eczema-market/
Global Chronic Hand Eczema (CHE) Market – Competitive Landscape
Various pharmaceutical companies are engaged in the development and marketing of topical steroids, immunosuppressants, and emollients specifically designed to manage chronic hand eczema. Companies focusing on biotechnological advancements may contribute to the development of novel therapies for chronic hand eczema. Research in immunology and targeted therapies might play a role in introducing more effective treatments. Entities specializing in dermatology products and treatments may have a significant presence in the chronic hand eczema market.
Some of the Key Players in the Global Chronic Hand Eczema Market Include –
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- LEO Pharma
- Galderma S.A.
- Sanofi
- GlaxoSmithKline
Global Chronic Hand Eczema (CHE) Market – Growth Drivers
The rising prevalence of chronic hand eczema globally is a primary driver of global chronic eczema market growth. Factors such as changes in lifestyle, environmental exposures, and genetic predisposition contribute to the growing number of individuals affected by this condition. According to Biomed Central, the one-year prevalence of hand eczema was 15.8% (females 20.3% and males 10.0%). Ongoing research and development activities lead to the introduction of innovative and more effective treatments for chronic hand eczema. This includes topical steroids, immunosuppressants, and other dermatological therapies. Increased awareness among healthcare professionals and the general public regarding chronic hand eczema symptoms and available treatments can result in earlier diagnosis and intervention, driving chronic hand eczema market growth. Certain occupations, such as healthcare workers, cleaners, and those in food handling, face a higher risk of chronic hand eczema due to frequent handwashing and exposure to irritants. The continued emphasis on occupational safety may drive the demand for preventive and therapeutic solutions. The overall growth in healthcare spending, especially in dermatological care, can positively impact the chronic hand eczema market. This includes investments in research, development, and accessibility to advanced treatments.
Global Chronic Hand Eczema (CHE) Market – Restraints
The availability of a limited number of approved and effective treatments for chronic hand eczema poses a restraint. A lack of diverse therapeutic options can hinder the ability to address the varied needs of patients. Existing treatments for chronic hand eczema, such as topical steroids, may have side effects or limitations. Concerns about adverse reactions and long-term use issues can impact patient adherence to prescribed therapies. Difficulty in accurately diagnosing chronic hand eczema can delay appropriate treatment initiation. Improved diagnostic tools and standardization of diagnostic criteria are essential to overcome this restraint. The cost of certain medications and ongoing dermatological care can be a barrier for patients seeking treatments. Affordability and accessibility issues may limit the widespread adoption of specific therapies. Occupational exposure to irritants and allergens remains a significant factor contributing to chronic hand eczema. Implementing effective preventive measures in various occupational settings poses a challenge and may require concerted efforts. Economic uncertainties and fluctuations can impact healthcare budgets and spending. reductions in healthcare funding or budget constraints may limit investments in research and developments for new chronic hand eczema treatments
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/chronic-hand-eczema-market/
Global Chronic Hand Eczema (CHE) Market – Opportunities
Ongoing research efforts present opportunities for the discovery of novel treatments and therapeutic approaches for chronic hand eczema. Investing in R&D can lead to breakthroughs in understanding the condition and developing more effective interventions. Continued advancements in diagnostic technologies, telemedicine, and digital health applications create opportunities for improved diagnosis, monitoring, and personalized treatment plans for individuals with chronic hand eczema. Emphasis on personalized medicine allows for tailored treatment strategies based on individual patient’s characteristics. This approach can enhance treatment efficacy and patient outcomes in chronic hand eczema.
Global Chronic Hand Eczema (CHE) Market – Geographical Insight
The market for chronic hand eczema is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & and Africa. North America is the largest market for chronic hand eczema due to the higher prevalence observed, influenced by factors like occupational exposures, lifestyle, and genetic predisposition. Robust healthcare infrastructure supports diagnosis and treatments. Western Europe and Northern European countries with high standards of living, like Germany and the UK, have a notable incidence of chronic hand eczema. Asia-Pacific countries such as China, Japan, and South Asia occupational factors, urbanization, and lifestyle changes contribute to chronic hand eczema prevalence.
Global Chronic Hand Eczema (CHE) Market – Key Development
- FDA approves Dupixent® as the first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
- On May 18, 2021, LEO Pharma initiated the first phase 3 clinical trial with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema.
- On October 15, 2020, Molnlycke launched new skin-friendly Biogel® surgical gloves to reduce the risk of allergic contact dermatitis for surgeons and nurses.